Breaking News

Mylan Appoints Strategic Ops EVP

By Kristin Brooks | January 9, 2014

Gulfo brings extensive industry experience from Pfizer

Adele Gulfo has been appointed executive vice president, Global Collaboration and Strategic Operations at Mylan, Inc., and will serve as a member of the executive leadership team.
 
Prior to joining the company, Ms. Gulfo served as regional president of Latin America in Pfizer's Emerging Markets Business Unit, where she led a team of more than 4,000 operating across more than 23 countries. Previously, she served as president and general manager of Pfizer's U.S. Primary Care Business Unit, which included the Managed Markets organization for all of Pfizer's Biopharmaceutical Business Units. Earlier in her career at Pfizer, she was instrumental in the launch of Lipitor, and was recognized for developing medical and public education campaigns that helped to establish the significance of lowering cholesterol in preventing and managing heart disease.
 
Additionally, Ms. Gulfo served as vice president of business development, Innovation and Design for Launch at AstraZeneca, and has been awarded five U.S. patents for innovative packaging designed to help patients adhere to their medicines.
 
Mylan chief executive officer Heather Bresch said, "Adele's rich and diverse experience in the pharmaceutical industry will bring significant strategic value and leadership to Mylan in numerous areas. We believe Adele's expertise will support many of our key growth drivers, including our expansion in Latin America, the development and expansion of our global Specialty franchise, and the development of global commercial strategies to maximize key upcoming launches of increasingly complex generic products, such as in the biologics and respiratory areas.”
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks